anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a sustained release tablet containing talniflumate. More specifically, the present invention relates to a talniflumate sustained release tablet formed as a drug coated tablet comprising a cored tablet and a double layered tablet or a drug coating layer. A solubilizing aid is used to increase the solubility of talniflumate which is an insoluble drug in the tablet. The tablet contains hydrophilic polymers to stablize the sustained release in the user's body. The sustained release tablet containing talniflumate according to the present invention has a relatively easy manufacturing process and is able to control release rate. Also, the tablet has excellent release efficiency for gradually releasing drug components in the body at a constant rate, compared with conventional immediate release talniflumate 370, 720 mg formulations which are available. Therefore, the tablet has an advantage that the inconvenience of administering three times a day is relieved by administering once or twice a day.
The nasal deformity is an abnormality in the appearance and structure of the nose in cleft patients having unilateral cleft lip and palate (UCLP). It involves the displacement of the lower lateral nasal cartilage, oblique and short columella, depressed dome, overhanging nostril apex, and deviated septum. Difficulty in breathing and smelling are the main problems of this deformity. Rhinoplasty for CLP patients is very complicated due to the complex nature of this type of deformity, especially in wide and bilateral cleft patients it is quite challenging. The cleft width along with the nasal deformity and collapse in the nasal cartilage could affect the outcome of the surgical lip closure with the cleft width as a major factor affecting the tension produced in the closure and future collapse of the nose. There is a striking diversity in the literature regarding treatment protocols for UCLP, with no standardized management protocols . Clinical decision-making based on evidence is lacking due to the few randomized clinical trials comparing the effectiveness of different approaches. A recent systematic review conducted a comprehensive search aiming at identifying the different treatment protocols and effectiveness of using pre-surgical infant orthopedics (PSIO) and recommended the need for further well-designed and high-quality randomized clinical trials (RCTs) in this area due to the unstandardized protocols with high diversity. Various studies supported the positive effect of naso-alveolar molding (NAM) appliance therapy on nasal symmetry in UCLP treatment. The NAM therapy decreases the severity of the initial cleft deformity and repositions deformed nasal cartilage and alveolar process, which has many beneficial results in the surgery outcome. Taping has been assessed in infants with UCLP and was deemed successful as well by a few studies. To our knowledge, no RCTs are comparing the use of NAM therapy to taping with the use of nasal elevators on UCLP patients.
A tablet capable of giving prolonged acting medication, but not including a tablet as claimed in the parent Specification, comprises a substantially homogeneous mixture of a water-soluble medicament, e.g. procyclidine, hydrochloride, benzhexol hydrochloride and methylamphetamine hydrochloride, in a medium comprising a pharmaceutically acceptable solid substance, e.g. casein, zein or soya bean protein, which is sparingly soluble in but slowly digestible by the gastrointestinal fluids and is present in amount of from 10 to 70% by weight of the mixture, and a sparingly soluble pharmaceutically acceptable hydrophobic waxy binding agent which is solid at body temperatures, said binding agent being optionally mixed with a solid fatty acid or a pharmaceutically acceptable salt thereof.  The tablet may be in the form of compressed granules or may be in the form of an inner core also containing medicament around which is a layer of the above mixture.  The mixture may itself be coated with non-medicated and/or medicated layers.  The binding agent consists of one of the following or a mixture thereof:-vegetable and animal waxes, e.g. beeswax, Japan-wax, spermaceti, paraffin wax, carnauba wax and wool fat; or a solid hydrogenated fixed oil or fat e.g. castor, palm or lard oils.
BACKGROUND: Maternal obesity (MO) increases fetal androgen concentrations, the prevalence of macrosomia, and predisposes offspring to metabolic dysfunction in later life, especially males. These risks may be, in part, the result of increased liver-specific androgen signalling pathway activity in utero. Androgen signalling activity can be suppressed by androgen metabolism via cytochrome P450 (CYP) isoenzymes (CYP2B6, CYP3A) or through inhibition of the full-length androgen receptor (AR-FL) via the antagonistic isoform, AR-45. We hypothesised MO impairs CYP enzyme activity and AR-45 expression in male fetal livers, thereby enhancing activity of androgen signalling pathways.
METHODS: Nine months prior to pregnancy, nulliparous female baboons were assigned to either ad libitum control or high fat diet. At 165 day (d) gestation (term, 180 d) fetal liver was collected (n = 6/sex/group). CYP activity was quantified using functional assays; subcellular AR expression was measured using Western blot.
RESULTS: CYP2B6 and CYP3A activity, and nuclear expression of AR-45, was reduced in MO males only. Nuclear AR-45 expression was inversely related with fetal body weight of MO males only.
CONCLUSIONS: Reduced CYP2B6 and CYP3A activity in conjunction with decreased nuclear AR-45 expression may enhance liver androgen signalling in males from MO pregnancies, thereby increasing the risk of macrosomia, as well as metabolic dysfunction in later life.
Methods, apparatus and computer-readable media are disclosed for gathering medical, health, and wellness related information for a consumer based on a health profile of the consumer. Health and medical information for a consumer is gathered based on a health profile of the consumer. A health profile associated with a consumer is accessed and maintained by a service provider. The health profile has numerous "events" reflecting health, medical, and wellness characteristics of the consumer. Information relevant to the consumer based on the health profile is retrieved from numerous external sources, such as Web servers and library files, at certain predetermined time intervals or on demand by the consumer. Relevant information is displayed in a user interface in a manner that allows efficient evaluation of the information by the consumer. In addition , the health and medical profile of the consumer can be modified through the user interface.
BACKGROUND: We sought to evaluate the associations of chest pain and dyspnea with the long-term risk of cardiovascular disease including coronary disease, heart failure, atrial fibrillation, and stroke.
METHODS: In 13,200 participants without cardiovascular disease in the Atherosclerosis Risk in Communities study (1987-1989), chest pain was categorized into definite angina, possible angina, non-anginal chest pain, and no chest pain using the Rose questionnaire. Dyspnea was categorized into grades 3-4, 2, 1, and 0 by the modified Medical Research Council scale. The associations of chest pain and dyspnea with incident myocardial infarction, heart failure, atrial fibrillation, and stroke over a median follow-up of ∼27 years were quantified with multivariable Cox models.
RESULTS: Definite angina and possible angina were associated with myocardial infarction (adjusted hazard ratios [HR] 1.80 [95%CI 1.45-2.13] and 1.65 [1.27-2.15]). Although lesser magnitude than myocardial infarction, both definite and possible angina were associated with heart failure. For atrial fibrillation, possible angina showed higher HR than definite angina. Dyspnea showed similar HRs for myocardial infarction and heart failure in grades 3-4 (2.00 [1.61-2.49] and 1.94 [1.62-2.32]). Stroke was least associated with chest symptoms. Chest pain and dyspnea significantly improved the discrimination of cardiovascular disease except stroke, beyond traditional risk factors.
CONCLUSIONS: In individuals without cardiovascular disease, chest pain and dyspnea were independently associated with incident cardiovascular disease for about 3 decades, suggesting the need for evaluating chest pain from a broader perspective of cardiovascular disease beyond coronary disease and the importance of dyspnea for cardiovascular risk assessment including myocardial infarction.
The present invention discloses an amino acid sequence encoded as SEQ? ID? Use of the polypeptide of No.1 or a homologous amino acid sequence thereof. Since the disclosed amino acid sequence of the present invention is encoded as SEQ? ID? The polypeptide of No.1 or its homologous amino acid sequence has the ability to regulate transcription of multiple genes or expression of multiple targets, and therefore, the polypeptide or its homologous amino acid sequence has the following effects: firstly, the method is applied to multiple parts of an individual and acts on multiple gene targets; second, treatment of inflammation or disorders involving an inflammatory response; thirdly, the disease symptoms of liver fat deposition are inhibited; fourthly, the efficacy of inhibiting fat accumulation; fifthly, the effect of preventing muscular atrophy; sixthly, the diabetic complication is reduced.
The invention discloses Chinese magnoliavine hypoglycemic parasitic tea. The invention utilizes the Chinese magnoliavine fruit parasitic, the broadleaf holly leaf parasitic, the yellow tooth tea parasitic and the stevia parasitic to prepare the tea, thereby enriching the forms and the types of the tea. Fructus Schisandrae has effects in astringing lung, nourishing kidney, promoting fluid production, arresting sweating, and arresting seminal emission. The broadleaf holly leaf has the functions of dispelling wind and clearing heat; improving eyesight and promoting fluid production. Headache due to wind-heat; dental pain; conjunctival congestion; purulent otitis media; aphtha; fever with polydipsia; diarrhea; dysentery is caused. Stevia rebaudiana has the effects of regulating blood pressure, softening blood vessels, reducing blood fat, reducing blood sugar and urine sugar, inhibiting bacteria, stopping bleeding, relieving pain, losing weight, beautifying, nourishing yin, promoting the production of body fluid, helping digestion, promoting the functions of pancreas and spleen and stomach, and clearing away heat and toxic materials. Can be used for treating diabetes, and hypertension. The parasitic plants also have the similar efficacy to the host plants, and the parasitic plants are convenient to drink after being made into a tea form, have thick and mellow mouthfeel and have a certain conditioning and helping effect on the phenomenon of blood sugar rise of a human body.
Patient will receive 20 mL sterile saline flushes into their catheter by study team members every 6 ± 2 hours. If patients are receiving intrapleural tissue plasminogen activator and deoxyribonuclease therapy, each treatment will be considered one flush.
Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should be used with caution with levalbuterol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

### 1\. Beta-blockers

Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists such as Levalbuterol HCl Inhalation Solution, but may also produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

### 2\. Diuretics

The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics.

### 3\. Digoxin

Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of racemic albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving levalbuterol HCl and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and Levalbuterol HCl Inhalation Solution.

### 4\. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants

Levalbuterol HCl Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of levalbuterol HCl on the vascular system may be potentiated.
Preterm delivery, defined as delivery before 37 weeks of completed gestation (259 days), is a major cause of neonatal morbidity and mortality. Despite extensive research, preterm birth still accounts for 5-10% of all deliveries in developed countries and rates are on the increase, including in the UK. While mortality associated with preterm delivery has declined due to use of antenatal steroids and improvements in neonatal intensive care, preterm babies still remain at risk of major complications. These include respiratory distress syndrome, necrotising enterocolitis, retinopathy of prematurity, sepsis, intraventricular haemorrhage, periventricular leucomalacia and long-term cognitive and sensory impairment. Two major determinants for the mortality and morbidity of babies born preterm are gestation at delivery and birthweight. Prematurity therefore carries significant cost implications to both healthcare services and society in general. High hemoglobin along with anemia was examined in an observational study. At entry to care, which ranged between 6 and 8.4 wk gestation, women with hemoglobin levels exceeding 130g/L had a greater than twofold increase in risk of preterm delivery and infant low birth weight. Neither risk was statistically significant, however, because of the small numbers with high hemoglobin. Similarly, a concentration of the iron storage protein, ferritin, that is high for the third trimester of pregnancy is also associated with an increased risk for preterm and very preterm delivery. Over the last twenty years, interest has been shown in using ultrasound parameters or Doppler studies of fetal blood to assess fetal anaemia. Middle cerebral artery Doppler has taken over and has replaced amniocentesis as a screening test for fetal anaemia in high risk pregnancies.
If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay [see Dosage and Administration (2)]. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level. Use of a reference laboratory is recommended when a qualified one-stage clotting assay or chromogenic assay is not available locally.

Monitor for the development of Factor VIII inhibitors. If bleeding is not controlled with ALTUVIIIO and the expected factor VIII activity plasma levels are not attained, perform an assay to determine if Factor VIII inhibitors are present (use Bethesda Units to titer inhibitors).
Tacrolimus can cause fetal harm. Follow applicable special handling and disposal procedures1 [see How Supplied/ Storage and Handling (16.4)].

PROGRAF injection must be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a concentration between 0.004 mg/mL and 0.02 mg/mL prior to use. Diluted infusion solution should be stored in glass or polyethylene containers and should be discarded after 24 hours. The diluted infusion solution should not be stored in a polyvinyl chloride (PVC) container due to decreased stability and the potential for extraction of phthalates. In situations where more dilute solutions are utilized (e.g., pediatric dosing, etc.), PVC-free tubing should likewise be used to minimize the potential for significant drug adsorption onto the tubing. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 

Due to the chemical instability of tacrolimus in alkaline media, PROGRAF injection should not be mixed or co-infused with solutions of pH 9 or greater (e.g., ganciclovir or acyclovir).
PURPOSE: To describe a surgical technique for posterior cerebral revascularization in pediatric patients with moyamoya arteriopathy. Here, we describe the clinical characteristics, surgical indications, operative techniques, and clinical and radiographic outcomes in a series of pediatric patients with moyamoya disease affecting the posterior cerebral artery (PCA) territory.
METHODS: A retrospective single-center series of all pediatric patients with moyamoya disease who presented to our institute between July 2009 through August 2019 were reviewed. The clinical characteristics, surgical indications, operative techniques, and long-term clinical and radiographic outcomes of pediatric moyamoya patients with PCA territory ischemia were collected and analyzed.
RESULTS: A total of 10 PCA revascularization procedures were performed in 9 patients, 5 female, ages 1 to 11.1 years (average 5.2 years). Complications included 1 stroke, with no infections, hemorrhages, seizures, or deaths. One patient had less than 1 year of radiographic and clinical follow-up. In 8 of 9 patients with at least 1 year of radiographic follow-up, there was engraftment of surgical vessels present in all cases. No new strokes were identified on long-term follow-up despite the radiographic progression of the disease. In the 8 cases available for analysis, the average follow-up was 50.8 months with a range of 12 to 117 months.
CONCLUSIONS: PCA territory ischemia in patients with progressive moyamoya disease can be surgically treated with indirect revascularization. Here, we describe our experience with PCA revascularization procedures for moyamoya disease, including pial pericranial dural (PiPeD) revascularization and pial synangiosis utilizing the occipital artery. These surgical options may be useful for decreasing the risk of stroke in pediatric moyamoya patients with severe posterior circulation disease.
A method, computer system, and a computer program product for pre-authorization is provided. The present invention may include identifying a treatment for a medical condition that yields a positive outcome. The present invention may also include identifying a plurality of key features in the identified treatment. The present invention may then include identifying a plurality of features within the plurality of key features that can be applied to a patient. The present invention may further include identifying a stakeholder based on the identified plurality of features applied to the patient. The present invention may also include authorizing the identified stakeholder. The present invention may then include creating a new block based on the authorized stakeholder. The present invention may further include adding the new block to a blockchain network for processing authorizations.
A side effect of some volatile anesthetics, such as isoflurane and desflurane, is enhanced automaticity, accounting for secondary atrial pacemakers. Volatile anesthetics also have varying effects on the AV node and His-Pukinje system. These agents also prolong the QT interval and, for this reason, volatile anesthetics as a group have at times been avoided for atrial fibrillation ablation due to the fear that they may affect the efficacy of the ablation and increase recurrence. However, sevoflurane does not have the effects shown for other volatile anesthetics cardiac conduction. At this point there has not been a study comparing propofol, a non volatile anesthetic typically used in these cases, to sevoflurane, a volatile anesthetic, to determine if volatile anesthetics should be avoided during these procedures. This study will challenge the existing belief that sevoflurane increases the length of time to ablate atrial fibrillation and also decreases the efficacy of the ablation.
Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
We propose to investigate the possible efficacy of combination daclizumab and sirolimus therapy to induce peripheral immune tolerance in participants presenting with non-infectious intermediate and posterior uveitis. This will be performed using a Phase I/II pilot study. Subjects on daclizumab monotherapy will receive a 6 mg loading dose of oral sirolimus at week 0, followed by a 2 mg dose every other day for 2 weeks. If tolerated, the subject will be increased to a 2 mg daily dose. After one year of combination therapy, the subject will be tapered off daclizumab first and then sirolimus. The primary outcome will be the ability of the participant to be successfully tapered off daclizumab and sirolimus while their disease remains quiet (vitreous haze less than or equal to Trace) for 24 weeks on no systemic immunosuppressive medications (approximately week 134).
A novel approach to the development of a personalized vaccine. This approach is based on: A) sequencing of the gag gene from an HIV-infected individual treated with antiretroviral therapy; B) sequencing of the HLA alleles of the same individual; C) selecting the epitopes recognized by the individual's own HLA Class I within the highly-conserved Gag 256-377 , Gag 147-169  and/or Gag 225-251  amino acid sequences. An original algorithm that designs the target peptide for the vaccine starting from viral and HLA sequences of an individual with HIV/AIDS, forms the core of the present invention. The original algorithm makes extensive use of existing open- source software for protein design. The peptides designed in this manner and accordingly synthesized may be exploited as a therapeutic vaccine against HIV/AIDS. Vehicles for such peptides may be an individual's own dendritic cells pulsed with the peptide combination or a specific viral or DNA vector leading to intracellular expression of the viral peptides. The present vaccine approach may contribute to control of viremia once antiretroviral therapies are suspended.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic which contains an extract from a specific plant in Aristolochiales as an active ingredient and has excellent skin-whitening effect with no problem on safety on application. SOLUTION: An extract from the whole body of Aristolochia debilis Sieb. et Zucc is used as an active ingredient for this skin cosmetic. In the extraction of Sesbania grandiflora, a water-soluble organic solvent, for example, methanol, propylene glycol, acetone or the like or water-containing water-soluble organic solvent, for example, acetone or dioxane is preferably used. The content of the Aristolochia debilis Sieb. et Zucc extract is preferably 0.01-10wt.%, particularly 0.01-5wt.% based on the whole skin cosmetic. This skin cosmetic is effective for improving skin dry feeling, gloss defect, fine wrinkles and roughening. This skin cosmetic is in the forms of, for example, skin lotion, milk emulsion, cream, pack, foundation cosmetic, lipstick, bath medicine and the like.